Start here if you're new
what it is
Anavex is a tiny biotech trying to turn brain-disease trial data into approved drugs and, eventually, real sales.
how it gets paid
Last year Anavex Life Sciences made $5M in revenue. Alzheimer's program-related revenue was the main engine at $1.8M, or 36% of sales.
why growth slowed
Revenue fell 36.1% last year. The key number was $1 million of quarterly revenue because it shows this is still a clinical-stage story pretending to have a commercial forecast.
what just happened
Quarterly revenue was just $1M, but EPS of -$0.06 came in better than expected.
At a glance
B balance sheet — gets the job done, barely
80/100 earnings predictability — you can trust these numbers
-$0.54 fy2025 eps est
$2B fy2026 rev est
n/a operating margin
xvary composite: 50/100 — below average
What they do
Anavex is a tiny biotech trying to turn brain-disease trial data into approved drugs and, eventually, real sales.
This is not a scale story. It is a data story. Anavex has 42 employees, but it is running precision-medicine work in Alzheimer’s, Parkinson’s, and Rett syndrome, using biomarkers (biological signals) → a way to pick likely responders → so what: if that works, your odds improve in diseases where failure is common.
How they make money
$5M
annual revenue · their business grew -36.1% last year
Alzheimer's program-related revenue
$1.8M
flat
Rett syndrome program-related revenue
$1.3M
flat
Parkinson's program-related revenue
$0.9M
flat
Schizophrenia and other CNS programs
$0.6M
flat
Other research-related revenue
$0.4M
36.1%
The products that matter
lead clinical asset
blarcamesine (anavex 2-73)
single-asset setup
This is the whole story. If the lead Alzheimer’s program earns a workable regulatory path, the company matters more. If it does not, the equity story shrinks fast.
binary outcome
follow-on clinical angle
rett syndrome program
secondary proof point
Rett gives the pipeline a second place to look for validation. It helps, but it does not erase the fact that one company-level narrative still dominates.
readthrough matters
business reality
no approved cash engine
no commercial revenue
Here’s the thing: there is no mature product funding the rest of the pipeline. Cash on hand matters more because the business does not yet fund itself.
funding first
Key numbers
$2.0B
FY2026 sales est.
This is the whole bet. Published estimates show $2.0 billion next year versus just $5 million of annual revenue now.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: Anavex loses about $11 for every $1 it brings in.
$5M
annual revenue
This tells you the current business is tiny. The stock is pricing possibility, not a proven commercial machine.
1.55
beta
Beta → how much a stock swings versus the market → so what: you should expect sharper moves than the average stock.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for AVXL right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Quarterly revenue was just $1M, but EPS of -$0.06 came in better than expected.
The quarter looked less bad on losses, not stronger on sales. Revenue fell 23% vs. prior year, while EPS improved 57% from the year-ago period.
$1M
revenue
$0.06
eps
n/a
n/a
the number that mattered
The key number was $1 million of quarterly revenue because it shows this is still a clinical-stage story pretending to have a commercial forecast.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
AVXL’s risk profile is not generic biotech hand-waving. It is very specific: one lead asset, no commercial revenue, and a stock already trading like patience is running out.
med
The lead asset stays in limbo
The bull case depends on blarcamesine moving closer to approval. Delay is not neutral here. Delay keeps the company pre-revenue for longer.
If the EMA or FDA path gets more complicated, the valuation starts leaning harder on cash than on future product economics.
med
Cash is a cushion, not a permanent answer
$132M in cash and no debt is good news. It is not infinite news. Clinical programs absorb money long before they produce it.
If timelines stretch without a clear milestone, dilution moves from background risk to front-page risk.
med
One asset still dominates the story
Rett syndrome helps broaden the narrative, but the company is not diversified enough for one setback to be easily absorbed.
When a single program carries the thesis, one weak update does not trim the story. It rewrites it.
If approval slips, you are left with a company doing $5M in annual revenue and posting biotech-sized losses.
source: institutional data · regulatory filings · risk analysis
Pay attention to
regulatory
The EMA decision is the board’s main binary catalyst right now
A pending decision is not just another headline. It is the difference between the story staying theoretical and getting closer to commercial reality.
calendar
Estimated earnings on May 7, 2026 are really a cash-and-timeline update
You are not looking for a sales beat. You are watching spending discipline, runway language, and whether management clarifies the next regulatory step.
metric
Cash versus market cap tells you how much hope is still in the price
With $132M in cash against a $431M market cap, a large part of the valuation still depends on future approval value rather than current business output.
trend
The stock needs proof to escape the low end of its $3–$14 range
Biotech shares can drift for months on hope and then move hard on one filing. Until proof shows up, price weakness is not noise. It is the message.
Analyst rankings
earnings predictability
80 / 100
in human-speak, the reported numbers do not shock people much — but that says more about how thin the operating base is than about a mature earnings engine
source: institutional data
Institutional activity
institutional ownership data for AVXL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive